Prof. P.R. Vavia B.Pharm., M.Pharm., Ph.D. (Tech)

Professor of Pharmaceutics A-257, Center for Novel Drug Delivery Systems, Department of Pharmaceutical Science and Technology, Institute of chemical technology, [University under Section-3 of UGC ACT (1956)] Nathalal Parekh Marg, Matunga, Mumbai – 400 019 E-mail: [email protected] Tel. No. 91-22-2414 5616 (Extn.- 2220) Fax. No. 91-22-2414 5614 Degrees with name of university/institute:

B.Pharm. University / Institute : University of Mumbai Year : 1985

M.Pharm. University / Institute : University of Mumbai Field(s) : Advance Pharmaceutics Title of Thesis : Studies on Percutaneous Absorption of Ketoprofen Year : 1987

Ph.D.(Tech.) University / Institute : University of Mumbai Field(s) : Advance Pharmaceutics Title of Thesis : Development and Evaluation of Radioimmunoassay for Therapeutics Monitoring of Theophylline

Year : 1991

Research Interest:

 Cyclodextrins based drug delivery systems  Nanosponge based drug delivery systems  Bioencapsultion  Multiparticulte drug delivery system  Transdermal drug delivery systems  Protein and peptide drug delivery system  Lipid based colloidal formulations  Polymer synthesis for drug delivery  Modified release films  Liposome based Drug Delivery Systems  Melt Extrusion Technology  Oral liquid dosage forms  Techniques in solubilization Brief statement on current research activities: Keeping in mind, the constraints to efficient delivery of potential drug candidates and ample opportunities associated with design of non-infringing drug formulations as well as value added generic drug development sector, Prof. P.R. Vavia and his research group is currently involved in fundamental as well as industrial research. Research work based on cyclodextrin and their derivatives, nanosponge based drug delivery systems, Bioencapsulation of poorly soluble actives, modified release multiparticulate drug delivery systems, application of particle engineering strategies, transdermal drug delivery systems, techniques in solubilisation of poorly water soluble drugs, microemulsions, nanosuspensions, protein and peptide based drug delivery systems, synthesis and application of novel polymers and excipients is going on with expected outcomes of industrial applicability and scalability. Development and validation of analytical methods, In-vivo studies of developed formulations and preparation of CTD as per regulatory requirements of international markets has given equal importance to meet the international standards.

Courses taught:

B.Pharm, B.Tech Pharma, M.Pharm (Pharmaceutics, Advanced pharmaceutics, Pharmaceutical Analysis, Biopharmaceutics, Industrial Pharmacy)

Awards, Honours and Accolades:

 Research Fellow of Human Resources Development

 Junior Research Fellow of Department of Atomic Energy

 Senior Research Fellow of Department of Atomic Energy

 Fellow, Indian Pharmaceutical Association, 2003 awarded at Indian Pharmaceutical Congress, Chennai, Dec. 21st -23rd, 2003

 Johnson and Johnson, USA, Research Award (US$ 20,000), 2001.  U.P.Government National Award for an outstanding work done in the area of interaction with Industries, 2005.

 Maharashtra Fellow for Medical Sciences, 2006.

 Best Teacher’s Award, University Institute of Chemical Technology at undergraduate level, 2007.

 Distinguish Teacher Award, Maharashtra Pharmacy Association, 2009.  “Incentives to Meritorious Teachers”, Dr. K. H. Gharda Reward, Board of Governers, Institute of Chemical Technology, 2009.

 Best Teacher’s Award, University Institute of Chemical Technology at undergraduate level, 2010.

Professional Activities:

 Life member, Indian Pharmaceutical Association

 President, Indian Pharmaceutical Association (2002-2004) (Maharashtra State Branch)

 Member, Association of Pharmacy Teachers of India (APTI)

 Member, Royal Pharmaceutical Society of Great Britan (Hon. Membership)

 Inspector appointed by Pharmacy Council of India for Inspection of Institutions

 Inspector appointed by AICTE for Inspection of Institution

 Member, Editorial board of Indian Journal of Pharmaceutical sciences

 Expert Member, DSIR for inspection of industrial R & D facility

 Nominee of Vice-chancellor for appointment of teachers of Mumbai University

 Member, International Advisory board, Asian Oceanic Cyclodextrin League

 Scientific Convener, Indian Pharmaceutical Congress Association, 2006-2009.

 Member of Italian Cyclodextrin League.

 Convener, 5th Young Innovative Choice Competition (YICC) and Young Research Competition (YRC), 2010-2011

 Reviewer of  AAPS Pharm Sci-Tech  International Journal of Pharmaceutics  Nanomedicine: Nanotechnology, Biology, and Medicine  Indian Journal Pharmaceutical Sciences  Pharmaceutical research  Journal of pharmacy and Pharmacology  AIChE Journal  Journal of Controlled Release

Industrial interaction

(a) Past  Novartis India Ltd.

 Panacea Biotec.

 Unichem Laboratories Ltd.

 Bayer India Ltd.

 Glenmark Pharmaceuticals Ltd.

 Cipla Ltd.

 Burroghs Wellcome.

 Jhonson & Jhonson Ltd.

 Medicap Ltd. (Bangkok, Thailand.)

 Atlantic Pharma

 Bajaj Healthcare Pvt. Ltd.

 Indoco Ltd.

 Themis Laboratories Ltd.

 Choice Laboratories Ltd.

 Goldshield Inc. (UK)

 Oman Pharmaceuticals, Oman.

 Dr. Reddys Lab.

 Bayer India Ltd.

 Macleods Laboratories Ltd.

 Colorcon Asia Pacific

 Rusan Pharma Ltd.

 BASF

(b)Current

 Kusum Health Care

 Nippon synthetic chemical industries Ltd

 Raptim  Uni-Sankyo Ltd.  Cyril Healthcare Pvt Ltd.

Master students Guided: 38

Ph.D Students Guided: 29

Current research students: Masters Students: 06 Ph.D Tech. Students: 18

Sponsored Projects:

(a) Previous:

1. Sponsor :Franco India Pharmaceuticals Limited

Title :Design and evaluation of diclofenac gel

Total Amount : Rs. 10,000/-

2. Sponsor : Cipla Limited

Title :Development and evaluation of topical formulations.

Total Amount : Rs. 1.5 lakhs

3. Sponsor :Johnson & Johnson Limited

Title :Evaluation of anti-fungal creams and development of validated analytical method

4. Sponsor : Chin Chem.

Title : Design of sustained release isosorbide dinitrate pellet formulation

Title : Development and evaluation of acyclovir liposomal gel formulation

6. Sponsor :UDCT Golden Jubilee Research Fund

Title : Synthesis and evaluation of terpolymer for transdermal therapeutic system

7. Sponsor : Unichem Laboratories

Title : Development of Novel drug delivery system

Total Amount : Rs. 1 lakhs

8. Sponsor : Department of Atomic Energy (DAE), BRNS

Title : Development of medicated polymeric controlled release films of cardiac and contraceptive drugs

9. Sponsor : All India Council for Technical Education (AICTE) (TAPTEC)

Title : Development of novel and industrially feasible transdermal drug delivery systems

10. Sponsor : Janssen Cilag Pharmaceuticals, Johnson & Johnson, USA Title : Use of lipid synthesis inhibitors and liposomes for enhancement of antifungal efficacy

Total Amount :US$ 20,000/-

11. Sponsor :Bayer India

Title : Development of double layer tablet of pseudoephedrine and cetirizine

12. Sponsor : Bayer India

Title : Development of Moxifloxacine Tablets

13. Sponsor : Mac Laboratories

Title : Development of Novel drug delivery system

14. Sponsor :Rohm Pharma, Germany

Title : Eudragit RL PO based drug-in-adhesive transdermal system of estradiol

Total Amount : DM. 1500/-

Title : Evaluation of Diclofenac Sodium Topical Gels

16. Sponsor : Glenmark Pharmaceuticals

Title :Evaluation of topical Anti-fungal formulations

17. Sponsor : Choice Limited

Title : Development and evaluation of Herbal Cosmetic formulations

18. Sponsor : Orochem Technologies Inc.

Title : Development of Herbal Cosmetic formulations

Total Amount :US $ 6,000/-

19. Sponsor : Rusan Pharma

Title : Development of New drug delivery systems

Total Amount : Rs. 3,60,000/-

20. Sponsor : Bayer Healthcare Ltd

Title : Development of Combination Product

21. Sponsor : BASF

Title: Evaluation of Kollidon VA64 by HME process for immediate release dosage form with different plasticizers and disintegrants.

22. Sponsor : UGC Major Research Project

Title: Design and Development of New Drug Delivery Systems of Anti-HIV Drugs

Total Amount : Rs. 10,71,000/- 23. Sponsor : Nippon Synthetic Chemicals Ltd.

Title: Studies on polymeric materials

Total Amount: Rs. 7,30,000/-

(b) Current:

1. Department of Biotechnology with industry collaboration Rs. 62,49,000/- Development and Evaluation of Nanoparticular Delivery System for Peptide drug

2. NAFETIC Facility for Novel Drug Delivery System Rs. 73,00,000/-

3. Kusum Health Care Rs. 95,00,000/- Development of Novel Formulations

4. Raptim Research Ltd. Development of In-Vitro methods Rs. 8,38,830/-

Products developed at UICT

No Description Industry partner 1 Atorvastatin Tablets 20mg (ATSTAT) 2 S(-)Amlodipine Tablet 2.5 mg & 5mg (SAMLOPIN) 3 Carbamazepine SR Tablet 400mg (MEZACAR 400) Serratiopeptidase Enteric Coated Tablet 10mg 4 (SERRATA) 5 Aspirin Enteric Coated Tablet 75mg (LOSPIRIN) 6 Carbamazepine IR Tablet 200mg (MEZACAR 200) Pantoprazole Enteric Coated Tablet 40mg Kusum Healthcare Ltd 7 (ZOLAPAN) 8 Oxcarbazepine Tablet 300 mg (OXAPINE) 9 Itraconazole Tablets 100mg (ESZOLE) 10 Citicholine Tablets 500mg (NERODAR) S(-)Amlodipine Atorvastatin Tablets 11 (AMLOSTAT) 12 Clopidogrel Tablets (CLOPIGREL) 13 Metformine Acarbose Tablet (GLUCOBAY M 25 & Bayer Pvt Ltd GLUCOBAY M 50) 14 Rofecoxib Tablets (ROFF-BCD-50) Unichem Pvt Ltd 15 Fentanyl Transdermal Patch (FENSTUD) Rusan Pvt Ltd

Patents:

 WO2006123354 ORAL PHARMACEUTICAL COMPOSITION

Jyotsna Torne, Pradeep R. Vavia, Satyen Torne, Shankar Swaminathan, Velidi Vijaya, Apichai Chancharusiri, Mehta Snehal, Mukund Pornchai, Wongpayak Rajesh, Madhav Pai

 A process for manufacture of an oral sustained release Tablet dosage form having one or more drugs in non-gas generating, floating, swellable and bioadhesive carrier composition. P.R.Vavia, Rajesh Shear, Paras Jain and Mahesh Chavanpatil. (Indian Patent)

Indian Patent Filed (Complete Specification):

 Controlled release composition of macrolide antibiotics. P.R.Vavia, Snehal Bhat (Indian Patent)

 Biocapsules for drug delivery P.R.Vavia, Sangwai M.B. (Indian Patent)

 Novel silicone pressure sensitive adhesive composition for transdermal drug delivery P. R. Vavia, Khire Achyut (Indian Patent)

 Amine resistant and non resistant silicone adhesive formulations of fentanyl and devices for transdermal delivery P. R. Vavia, Goyal Gaurav (Indian Patent)

 Pharmaceutical formulation comprising combination of Metformin and acarbose P. R. Vavia, Khan Mohammed Majed, Chavan Sandip (Indian Patent)

 Oral pharmaceutical composition for controlled release of drug P. R. Vavia, Sharad Darandale (Indian Patent)  Stable transdermal system of oxybutynin P. R. Vavia, Goyal Gaurav (Indian Patent)

 Lornoxicam cyclodextrin and amino acid ternary inclusion complex P. R. Vavia, Dinesh Brahmane (Indian Patent)

 A novel multiparticulte controlled porosity osmotic pump of oxybutynin hydrochloide P. R. Vavia, Sharad Wawdhane (Indian Patent)

 Solid antiretroviral oral composition P. R. Vavia, Goyal Gaurav (Indian Patent)

 Oral concentrated nanoemulsion based formulation of tetrahydrolipstatin P.R.Vavia, Sangwai Mayur (Indian Patent)

 A novel hollow multiparticulate excipient for drug delivery P.R.Vavia, Chavan Sandip (Indian Patent)

 Novel immediate release telmisartan composition P.R.Vavia, Sangwai Mayur (Indian Patent)

 Multiparticulate controlled porosity osmotic system P.R.Vavia, Saindane Nilesh (Indian Patent)

 Pharmaceutical composition for immediate release of weakly acidic potent drugs P.R.Vavia, Vora Lalit (Indian Patent)

 A pharmaceutical composition of niosomal gel for the topical delivery of P.R.Vavia, Kumbhar Deepak (Indian Patent)

 Oral Composition of calcium P.R.Vavia, Sangwai Mayur (Indian Patent)

 Pharmaceutical composition containing crosslinked cyclodextrin polymer P.R.Vavia, BrahmneDinesh (Indian Patent)  Ezetimibe nanosuspension and preparation method thereof P.R.Vavia, Monpara Jasmin (Indian Patent)

Indian Patent Filed (Provisional Application):

 Solid pharmaceutical composition of propofol P.R.Vavia, Darandale Sharad (Indian Patent)

 Solid lipid nanoparticles based formulation of antifungal agent and preparation method thereof P.R.Vavia, Wavikar Preeti (Indian Patent)

 Solid oral pharmaceutical composition comprising of poorly water soluble drug P.R.Vavia, Pawar Smita (Indian Patent)

 Multiparticulate extended release pharmaceutical composition of carbamazepine P.R.Vavia, Chavan Sandip (Indian Patent)

 Nanoformulations for brain delivery P.R.Vavia, Wavikar Preeti (Indian Patent)

 Sublingual formulation of buprenorphine hydrochloride P.R.Vavia, Yeola Gaurav (Indian Patent)

 Pharmaceutical nasal spray composition for delivery of drugs P.R.Vavia, Saindane Nilesh (Indian Patent)

Seminars and Invited Talks

International:

 Invited as Speaker at the 20th Cyclodextrin Symposium And Asian Cyclodextrin Conference, Chiba, Japan , 10th Sept. 2002.  Invited Speaker, Presentation of research papers at 3rd Asian Cyclodextrin conference, Tianjin, China, 8th -12th May, 2005.

 Invited Speaker, Presentation of research papers at 13th International Cyclodextrin Symposium, Totino, Italy, 14th -17th May, 2006.

 Invited Speaker, 2nd Congresso Nazionale, Chimica E Technologia Della Ciclodestrine Asti, Italy, 3rd -5th May, 2009.

 Invited Speaker, “Dissolution method development, SUPAC guidelines and biowaivers for pharmaceutical dosage forms” organized by Electrolab India, Thailand, 3rd Sept. 2009.

National

 Invited as Speaker and chief guest at the One day seminar on ‘Recent Advances in Novel Drug Delivery Systems’ organized by IPA Pune Branch 2008.

 Invited as Speaker at the AICTE sponsored National seminar on ‘Current Trends in Novel Drug Delivery Systems’ R.C. Patel Institute of pharmaceutical sciences and research, Shirpur, Dhule August 2008.

 Invited as Speaker at the University of Pune sponsored sminar on ‘Formulation Development ... problem based learning’, SKNCOP, Kndhawa, Pune October 2008.

 Invited as Speaker at the ICPPS-2009 and IPA convention – 2009, DPSAR University, New Delhi, March 2009

 Invited as Speaker at the IPA sponsored seminar on ‘Stability Studies in Pharmaceuticals’, Sci-Tech Center, Mumbai, May 2009

 Invited as a Speaker in University of Pune sponsored two day state level seminar on “Recent trends in pharmaceutical technology” 5th & 6th Feb. 2010

 Invited as a Co-chairman, IPA convention-2010, Chennai, Tamil Nadu.

 Invited speaker, 62nd Indian Pharmaceutical Congress, Manipal 17th – 19th Dec. 2010.  Attended seminar on “CSR: Role of Pharmaceutical Sector in fight against HIV/AIDS and TB” Mumbai, 27th April, 2010.

 Chief Guest and the speaker, AICTE National seminar on “Nanotechnology: A versatile tool in drug design and technology” Organized by Agnihotri college of pharmacy, Wardha, Nagpur, 7th June 2010.

 Invited speaker, Leveraging technological advances in Novel Drug Delivery Systems, NDDS India, Mumbai, 19th-20th August 2010.

 Invited speaker, 62nd Indian Pharmaceutical Congress, Manipal 17th – 19th Dec. 2010.

 Invited speaker, “Advances and Trends in Drug Delivery Process” State level seminar, MIT college, Pune 5th -7th March 2011.

Conference/Symposia Presentations:

Total Research Presentations 204: (International-56, National-148)

1. Adhage N.A. and Vavia P.R., "Inclusion complexation of tolfenamic acid with - cyclodextrins", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

2. Mare V.S. and Vavia P.R., "Aspects of quality control of transdermal therapeutic systems-in-vitro drug release from transdermal patches of nitroglycerin", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

3. Soman A.A. and Vavia P.R., "Design of liposomal gel formulations of diclofenac sodium", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th- 21st December, 1997. 4. Kotiyan P.N., Bharti P.V. and Vavia P.R., "Synthesis and characterization of an adhesive polymer for transdermal therapeutic system", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

5. Dhole S.N. and Vavia P.R., "Design and evaluation of oral controlled release aspirin pellets by extrusion-spheronisation for cardiac patients", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

6. Soman A.A. and Vavia P.R., "Novel gel for nasal administration of vitamin B12" at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

7. Mare V.S. and Vavia P.R., "Design and formulation of monolithic type transdermal therapeutic system of nitroglycerin", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

8. Jain A.K. and Vavia P.R. "Optimization of Proliposome S as a penetraion enhancer", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th- 21st December, 1997.

9. Puthli S.P. and Vavia P.R., "High performance thin layer chromatographic determination of levonorgestrel", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

10. Quenim U.S. and Vavia P.R., "Significance of load-mapping in approximation of representative sampling in pharmaceutical coatings" at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

11. Kinalekar M.S. and Vavia P.R., "Enzyme preparation using alkalophilic Bacillus for the production of -cyclodextrins", at the 49th Indian Pharmaceutical Congress, Thiruvananthapuram, 18th-21st December, 1997.

12. Purohit V.S., Bharati P.V., Lele V.R. and Vavia P.R., Development of monolithic transdermal patch of Isosorbide dinitrate, at the 3rd International symposium on innovations in pharmaceutical Sciences and Technology, 7th-9th February, 1997.

13. Vavia P.R. and Puthli S.P., "Poly (lactide-co-glycolide) microspheres of levonorgestrel for parenteral contraception", at the 135th British Pharmaceutical Conference, London, U.K., 8th - 11th September, 1998. 14. Indap M.A., Bhosale S.C., Vavia P.R. and Tayade P.T., "Quercetin - cyclodextrin complex for chemotherapeutic investigation in cancer", Conference on Advances in clinical pharmacology and workshop on basics of clinical pharmacology, Mumbai, 1st - 3rd February, 1998.

15. Puthli S.P. and Vavia P.R., "Stability indicating high performance thin layer chromatographic determination of piroxicam", III International Symposium and Short Course on Separation Sciences, Bhopal, India, 23rd - 26th November, 1998.

16. Kotiyan P.N. and Vavia P.R., "Stability indicating high performance thin layer chromatography for the estimation of estradiol", III International Symposium and Short Course on Separation Sciences, Bhopal, India, 23rd - 26th November, 1998.

17. Kinalekar M.S., Kulkarni S. and Vavia P.R., "Simultaneous determination of alpha, beta and gamma cyclodextrins by HPLC method", III International Symposium and Short Course on Separation Sciences, Bhopal, India, 23rd - 26th November, 1998.

18. Puthli S.P. and Vavia P.R., "Studies on the effect of radiation sterilization on biodegradable micro spheres", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

19. Adhage N.A. and Vavia P.R., "Grinding: A method for -cyclodextrins inclusion complexation", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

20. Indap M.A., Bhosle S.C., Tayade P.T. and Vavia P.R., Preparation and antitumour activity of quercetin-hydroxy propyl -cyclodextrins inclusion complexation", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

21. Tayade P.T. and Vavia P.R., Evaluation of pharmacokinetic parameters of ketoprofen and ketoprofen -cyclodextrins in healthy Indian male volunteers", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

22. Kinalekar M.S. and Vavia P.R., "Optimization of ultrafiltration method as a tool for the continuous production of -cyclodextrins at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998. 23. Kotiyan P.N. and Vavia P.R., "Prevention of drug crystallization in monolithic transdermal systems of estradiol", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

24. Mare, V.S., Kotiyan, P.N. and Vavia, P.R., "Design and evaluation of acrylate based pressure sensitive adhesives for transdermal drug delivery systems", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

25. Adhage N.A., Soman A.A. and Vavia P.R., "Anti-inflammatory and analgesic activity of nimesulide--cyclodextrins inclusion complexation", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

26. Makhija S.N. and Vavia P.R., "Simultaneous estimation of pseudoephedrine and cetirizine by reverse phase HPLC", at the 50th Indian Pharmaceutical Congress, Mumbai, 10th - 13th December, 1998.

27. Kotiyan P.N., Bharti P.V. and Vavia P.R., "Transdermal systems of estradiol: fabrication and evaluation", at the 18th Pharmaceutical Technology Conference, Utrecht, The Netherlands, 13th - 15th April, 1999.

28. Soman A.A. and Vavia P.R., "Topical gel formulations: liposomal system for a non- steroidal antiinflammatory agent", at the 18th Pharmaceutical Technology Conference, Utrecht, The Netherlands, 13th - 15th April, 1999.

29. Adhage N.A. and Vavia P.R., "A milling method for producing a nimesulide-beta- cyclodextrin inclusion complex", at the 18th Pharmaceutical Technology Conference, Utrecht, The Netherlands, 13th - 15th April, 1999.

30. Puthli S.P., Bharadwaj Y.K., Majali A.B. and Vavia P.R., "A microparticulate parenteral drug delivery system produced from a biodegradable polymer of natural origin", at the 18th Pharmaceutical Technology Conference, Utrecht, The Netherlands, 13th - 15th April, 1999.

31. Mare V.S., Bharti P.V. and Vavia P.R., "Design and in-vitro evaluation of a 'Drug- in-adhesive' Transdermal System of Nitroglycerin", at the 18th Pharmaceutical Technology Conference, Utrecht, The Netherlands, 13th - 15th April, 1999. 32. Mare V.S. and Vavia P.R., "Design and fabrication of drug in adhesive transdermal systems of nitrate drugs using indigenous pressure sensitive adhesive", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

33. Kotiyan P.N. and Vavia P.R., "Vinyl acetate copolymer based drug-in-adhesive transdermal system of estradiol", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

34. Kotiyan P.N. and Vavia P.R., "Stability considerations in the development of trasdermal steroidal delivery system", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

35. Shakleya D.M. and Vavia P.R., "Enhancement of anti-inflammatory activity of diclofenac gel", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

36. Mare V.S. and Vavia P.R., "Controlling crystallization in transdermal patches of ISDN in polyisobutylene matrix", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

37. Adhage N.A. and Vavia P.R. "Pharmacodynamic studies of tolfenamic acid: - cyclodextrins inclusion complexes", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

38. Adhage N.A. and Vavia P.R., "Evaluation of pharmacokinetic parameters of nimesulide and nimesulide--cyclodextrin tablets", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

39. Makhija S.N. and Vavia P.R., "Stability indicating HPTLC method for the simultaneous estimation of pseudoephedrine and cetirizine", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

40. Tipre D.N. and Vavia P.R., "Degradation kinetic study and stability indicating HPTLC method of nitrendipine" at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

41. Tipre D.N. and Vavia P.R., "Simultaneous estimation of losartan potassium and hydrochlorothiazide using planar chromatography", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999. 42. Jain P.R. and Vavia P.R., "Development and validation of Stability indicating HPLC method of niotinic acid", at the 51st Indian Pharmaceutical Congress, Indore, 18th - 20th December, 1999.

43. Tipre D. N. and Vavia P. R., “Design and evaluation of Nitrendipine transdermal delivery system.”, at the 3rd International symposium on Advances in technology and Business Potential of new drug Delivery systems, Ootacamund, India, 30th-2nd sept., 2000.

44. Shakleya D. M. and Vavia P. R., “Carbopol in Opthalmic formulations.”, at the 3rd International symposium on Advances in technology and Business Potential of new drug Delivery systems, Ootacamund, India, 30th-2nd sept., 2000.

45. Kulkarni S.S. and Vavia P.R., “ Novel decongestant bilayered tablets in modified release dosage formsusing HPMC, at the 3rd International symposium on Advances in technology and Business Potential of new drug Delivery systems, Ootacamund, India, 30th-2nd sept., 2000.

46. Makhija S. N. and Vavia P.R., “Acrylate based osmotically controlled release systems.” at the 3rd International symposium on Advances in technology and Business Potential of new drug Delivery systems, Ootacamund, India, 30th-2nd sept., 2000.

47. Tipre D.N. and Vavia P.R., “Eudragit E100 based drug in adhesive transdermal system of Nicorandil.” at the 3rd International symposium on Advances in technology and Business Potential of new drug Delivery systems, Ootacamund, India, 30th-2nd sept., 2000.

48. Bhat S.S. and Vavia P.R., “Once daily sustained release antibiotic formulation, at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

49. Shakleya D..M.and Vavia P.R., “Topical gels of Meloxicam.” at the 52 nd Indian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

50. Makhija S.N. and Vavia P.R., “Osmotically controlled release systems of Pseudoephedrine” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000. 51. Jain P. R. and Vavia P. R.,” Sustained release Niacin tablets for cholesterol lowering.” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

52. Manjrekar P. N. and Vavia P. R., “Inclusion complex of Mefenamic acid in  - cyclodextrin: Preparation and properties.” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

53. Dawre F. D. and Vavia P. R., “Molecular encapsulation of Celecoxib in  - cyclodextrin.” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

54. Makhija S.N. and Vavia P.R., “Stability indicating HPLC method for Venlafaxine, a bicyclic antidepressant.” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

55. Bhat SS and Vavia P. R., “Estimation of macrolide antibiotic, Clarithromycin by colorimetric method.” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st- 3rd December, 2000.

56. Kulkarni S. S. and Vavia P. R., “Colorimetric estimation of Cisapride using MBTH from pharmaceutical dosage forms.” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

57. Tipre D. N. and Vavia P. R., “Concentration dependant photodegradation study of Nitrendipine in organic solvents. at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st-3rd December, 2000.

58. Shakleya D. and Vavia P. R.,”Reverse phase HPLC determination of Rifampicin from biological fluids.” at the 52ndIndian Pharmaceutical Congress, Hyderabad, 1st- 3rd December, 2000.

59. Tipre D.N. and Vavia P.R. , “Stabilisation of Nicorandil with cyclodextrin for oral and parenteral dosage forms.” at the 10th International symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA, Feb. 19-22,2001.

60. Makhija S.N. and Vavia P.R., “ Sustained release tablets of Venlafaxine, a non- tricyclic antidepressant.” at the 10th International symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA, Feb. 19-22,2001. 61. Shakleya D.M. and Vavia P.R., “ Bioavailability of Rifampicin tablet in combination with INH, Pyrazinamide and Ethambutol in healthy human volunteers.” at the 10th International symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA, Feb. 19-22,2001.

62. Chavanpatil M. and Vavia P. R., “The influence of absorption enhancers on nasal drug delivery of acyclovir.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

63. Manjrekar P. N. and Vavia P.R., “Preparation of inclusion complex of Tamoxifen citrate in -cyclodextrin and its evaluation against spontaneous mammary tumour.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

64. Karnik A. D. and Vavia P. R., “Novel gel-sol injection of Doxycycline hydrochloride for the treatment of periodontitis.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

65. Jadhav G. S., Dawre F. D. and Vavia P. R., “Meloxicam in -cyclodextrin: an approach to improve the therapeutic efficacy.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

66. Shakleya D. and Vavia P. R., “Carbopol® in ophthalmic formulation-II.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

67. Chavanpatil M., Dawre F. D. and Vavia P. R., “Study on absorption of Rofecoxib and its inclusion complex in -cyclodextrin by the rat everted intestinal sac model.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

68. Jadhav G. S., Makhija S. N. and Vavia P. R., “Pharmacokinetic studies of Venlafaxine SR tablets in healthy human volunteer.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

69. Shear R. S. and Vavia P. R., “Simple and rapid HPTLC estimation of Nimodipine.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001. 70. Bhat S. S. and Vavia P. R., “Stability indicating HPLC method for macrolide antibiotic, Clarithromycin.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

71. Shear R. S. and Vavia P. R., “Development of HPTLC method for Nicorandil from rat plasma.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

72. Jain P. R. and Vavia P. R., “Once daily sustained release niacin formulation.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

73. Manjrekar P. N. and Vavia P. R., “Evaluation of Anti-tumour activity of Diarylheptanoid from Curcuma species.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

74. Chavanpatil M. and Vavia P. R., “Simple and rapid High Perfomance Thin Layer Chromatographic estimation of Amikacin sulphate from Pharmaceutical Dosage form.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

75. Jain P. R. and Vavia P. R., “Development and validation of stability indicating HPLC method for Simvastatin.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

76. Choudhari S. V., Dawre F. D. and Vavia P. R., “Stability indicating HPLC method for Rofecoxib – A novel selective COX-2 inhibitor.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

77. Chavanpatil M. and Vavia P. R., “Estimation of Moxifloxacin in pharmaceutical dosage form by spectrophotometric and HPTLC method.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

78. Karnik A. D., Chavanpatil M. and Vavia P. R., “Development and validation of HPTLC method for the analysis of Doxycycline hydrochloride.” at the 53rd Indian Pharmaceutical Congress, New Delhi, Dec. 20th -23rd, 2001.

79. M.C.Patil and P.R.Vavia, “Enhancement of Nasal absorption of Acyclovir via Cyclodextrins”, at the 11th International Cyclodextrin Symposium at Reykjavik, Iceland, 5th – 8th May, 2002. 80. M.A.Indap, P. N. Manjrekar, P.R.Vavia, et.al., “ The bioflavonoid Quercetin: anti- tumor activity and pharmacological manipulations for increased therapeutic gains”, at the 18th UICC International Cancer Congress, Oslo – Norway, 30th June – 5th July, 2002.

81. M.C.Patil and P.R.Vavia, “ Once Daily Sustained Release Formulation of Cephalexin”, at the 4th International Symposium on Advances and Business Potential of Novel Drug Delivery Systems, Mumbai, India, 23rd – 25th July, 2002.

82. P.R. Jain and P.R.Vavia, “Amoxicillin Sustained Release for improved therapeutic efficacy”, at the 4th International Symposium on Advances and Business Potential of Novel Drug Delivery Systems, Mumbai, India, 23rd – 25th July, 2002.

83. P.R.Vavia and F.D.Dawre, “Preparation and Characterization of Beta-Cyclodextrin Complexes with Non-Steroidal Anti-Inflammatory Agents” at the 20th Cyclodextrin Symposium And Asian Cyclodextrin Conference, Chiba, Japan , 10th Sept. 2002.

84. P.R.Vavia, J.S.Torne and G.S.Jadhav, “Cyclodextrin Complex with Anti-HIV Drug” 20th Cyclodextrin Symposium And Asian Cyclodextrin Conference, Chiba, Japan , 10th Sept. 2002.

85. Dawre F. D. Torne J.S. and Vavia P. R., “Studies on Anti-inflammatory and Analgesic Activity of Celecoxib and its Inclusion Complex with -Cyclodextrin” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

86. Chavanpatil M. and Vavia P.R., “Development and validation of stability indicating HPLC method for Sumatriptan Succinate” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

87. Jain P.R., Chavanpatil M.D. and Vavia P.R.,“ High Performance Liquid Chromatographic Estimation of Ofloxacin From Human Plasma” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

88. Jain P.R., Chavanpatil M.D. and Vavia P.R., “ Development and Validation of Stability Indicating HPLC Method for Ofloxacin” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002. 89. Chaudhari S.V. and Vavia P.R, “Reverse phase stability indicating HPLC method of Terbinafine Hydrochloride” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

90. Manjrekar P. N. and Vavia P. R., “Inclusion complex of Diarylheptanoids in -cyclodextrin: Preparation and properties” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

91. Shah R.C. and Vavia P. R., “Molecular Encapsulation of Clonazepam in - Cyclodextrin” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

92. Tandale R. S. and Vavia P. R., “Precise and Accurate HPLC Method for Estimation of Clotrimazole and Beclomethasone Dipropionate in cream” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

93. J. Balakrishnan, D. M. Shakleya and P. R. Vavia, “Topical Nimesulide Gel” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

94. R. C. Shah, D. M. Shakleya and P. R. Vavia, “Fast Acting Diclofenac Diethylammonium Gel” at the 54th Indian Pharmaceutical Congress, Pune, Dec., 13th –15th, 2002.

95. Rajendra S.T. and Vavia P. R., “Estimation of Rofecoxib and counterirritants from novel emulgel using new sensitive and precise HPLC method” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

96. Tandale R.S. and Vavia P. R. “Novel Rofecoxib Emulgel for Effective Pain Management” at the 54th Indian Pharmaceutical Congress, Pune, Dec. 13th –15th, 2002.

97. P.R. Vavia, Jyotsna S. Torne, F.D. Dawre and Dilip Pawar, “Bioavailability Studies of Rofecoxib-Beta-cyclodextrin Tablets” Poster Presentation at 63rd International Congress of FIP, Sydney, Australia, 2002.

98. P.R. Vavia, Jyotsna S. Torne “Cyclodextrin Based Drug Delivery System of ANTI - HIV Drug” Poster Presentation at 63rd International Congress of FIP Sydney, Australia, 2002. 99. P.R. Vavia, P.R. Jain M.C. Patil, “Once Daily Controlled Release Ofloxacin formulation” Poster Presentation at 63rd International Congress of FIP Sydney, Australia, 2002.

100. Vavia P. R., Agnihotri S.M., “A novel biodegradable polymers for drug delivery” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st –23rd, 2004.

101. Vavia P.R., Jadhav G.J., “Development and validation of photostability indicating HPLC methods for Danazol” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st –23rd, 2004.

102. Vavia P.R., Choudhari S.V., “ Once daily sustained release cefadroxil formulation” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st –23rd, 2004.

103. Vavia P.R., Patel A.R.,“ Molecular encapsulation of fenofibrate in Beta- cyclodextrin” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st – 23rd, 2004.

104. Vavia P.R., Jadhav G.J., “Pharmacodynamic studies of valdecoxib and beta- cyclodextrin inclusion complex” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st –23rd, 2004.

105. Vavia P.R., Tandale R.S., “Estimation of valdecoxib and counter irritants for novel emulgel using new, sensitive and precise HPLC method” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st –23rd, 2004.

106. Vavia P. R., Agnihotri S.M., “Influence of process parameters on nanoparticle preparation performed by a double emulsion ultrasonication technique” NATCOSEB XI, Mumbai.

107. Vavia P. R., Sonaje G.R., Choudhari S.V. “Once daily sustained release formulation of cefadroxil” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st – 23rd, 2004.

108. Vavia P. R., Tandale R.S., “Development of Novel Valdecoxib Emulsion Gel with counter-irritants for effective pain management ” at the 55th Indian Pharmaceutical Congress, Chennai, Dec. 21st –23rd, 2004.

109. Vavia P. R., Torne J.S., “Solubility enhancement of anti-HIV drug – Nelfinavir Mesylate by Beta-cyclodextrin complexation” 5th Controlled Release Society symposia on Advances in Technology and Business potential in NDDS, 16th- 17th Feb. 2004.

110. Vavia P. R., Torne J.S., “Once daily sustained release formulation of anti-HIV drug – Stavudine” 5th Controlled Release Society symposia on Advances in Technology and Business potential in NDDS, 16th-17th Feb. 2004.

111. Vavia P. R., Jadhav G.J., “Development and pharmacodynamic evaluation of tablet containing inclusion complex of valdecoxib with beta-cyclodextrin” 5th Controlled Release Society symposia on Advances in Technology and Business potential in NDDS, 16th-17th Feb. 2004.

112. Vavia P. R., Tandale R.S., “Development of novel emulsion gel with counter irritants for effective pain management"5th Controlled Release Society symposia on Advances in Technology and Business potential in NDDS, 16th-17th Feb. 2004.

113. Vavia P. R., Bhat S.S., “Clarithromycin sustained release formulation for improved efficasy” 5th Controlled Release Society symposia on Advances in Technology and Business potential in NDDS, 16th-17th Feb. 2004.

114. Vavia P. R., Agnihotri S.M., “Development and evaluation of novel diclofenac sodium loaded polymeric colloidal dispersion system” 5th Controlled Release Society symposia on Advances in Technology and Business potential in NDDS, 16th-17th Feb. 2004.

115. Goyal Gaurav * and Vavia P. R., Topical Sildenafil Gel : A Novel Highly Permeable Delivery System For Erectile Dysfunction., 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

116. Torne J. S. and Vavia P. R., “Development of HPLC method for Self Micro- Emulsifying Drug Delivery System (Smedds) of immunosuppressant” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

117. Rajendra S. T. and Vavia P. R., “Novel Extended Drug Delivery Of Metformin” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004 , Kolkata.

118. Gajanan S. and Vavia P. R., “Once Daily Osmotic Tablet Of Oxybutynin Hydrochloride” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004. 119. Ashwini D. Karnik, A. Adhikary, S. Chaudhari, R. Tandale, Vavia P.R., “Development of Novel Fast disintegrating Tablet formulation of Cefuroxime Axetil” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

120. Ashok R. Patel and Vavia P. R., “Aceclofenac - β-Cyclodextrin Systems: Preparation, Characterization and In- vitro Evaluation”56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

121. Patel A.R. and Vavia P. R., “Evaluation of PVPVA as a carrier in Solid Dispersion” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

122. Jadhav G. S, Nandedkar T. D. and Vavia P. R, “Oral Contraceptive Activity of Novel Formulation of PRV-GJ-03 in Mice” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

123. Pathan S.M. , Jadhav G.S. and Vavia P.R., “Prepartion and Characterization of Inclusion Complex of Danazol with b-Cyclodextrin” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

124. Agnihotri S. M., Jadhav G. S. and Vavia P. R., “Development and Validation of Stability Indicating HPLC Method For Valdecoxib”, 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

125. Ripal G.J., Jadhav G.S. and Vavia P.R., “Development and Optimization of Tablet Formulation containing Inclusion Complex of Etoricoxib in b-Cyclodextrin” 56th Indian Pharmaceutical Congress, 3rd –5th Dec.2004.

126. Vavia P. R., Torne J.S., “Solubility enhancement of anti-HIV drug by Beta- cyclodextrin Inclusion complexation” 3rd Asian Cyclodextrin Conference, 8th-12th May, 2005.

127. Patel A.R. and Vavia P.R., “Effect of hydrophilic polymer on solubilization of fenofibrate by Cyclodextrin complexation” 3rd Asian Cyclodextrin Conference,China, 8th-12th May, 2005.

128. Patel A.R., Jadhav G.S. and Vavia P. R., “Interaction of Valdecoxib with Beta Cyclodextrin- Experimental and molecular modeling studies” 3rd Asian Cyclodextrin Conference, China, 8th-12th May, 2005. 129. Adhikary A.R., Karnik A.D., and Vavia P.R., “Development and Evaluation of Gastro-Retentive Drug Delivery System of Rantidine HCl using Two Different Approaches” 2nd International Symposium on Drug Discovery and Process Research, Belgaum, 10th to 12th February, 2006.

130. Ansari Khalid Akhter, Vavia P.R., “Development of Novel Sustained Release System: Disintegration Controlled Matrix Tablet with Solid Dispersion Granules of Felodipine” 2nd International Symposium on Drug Discovery and Process Research, Belgaum, 10th to 12th February, 2006.

131. Karnik A.D., Adhikary A.R. and Vavia P.R., “Development and Evaluation of Modified Release Tablets of Gliclazide 80mg” 2nd International Symposium on Drug Discovery and Process Research, Belgaum, 10th to 12th February, 2006.

132. Patel A.R., Ansari Khalid Akhter, Vavia P.R., “Emerging Trends in Nano- Enabled Aerosol Drug delivery System” 2nd International Symposium on Drug Discovery and Process Research, Belgaum, 10th to 12th February, 2006.

133. Shankar Swaminathan, Vavia P.R., “Nanosponge based Drug Delivery of Cilostazol” 2nd International Symposium on Drug Discovery and Process Research, Belgaum, 10th to 12th February, 2006.

134. Vavia, P.R., Swaminattan, S., Trotta, F., Cavalli, R., ” Applications of Nanosponges in Drug Delivery” XIII International Cyclodextrin Symposium , pp. 14-17, 2006.

135. Sonaje G.R. Vavia P.R., “Development of Sustained Release Tablet of Tizanidine HCl” 2nd International Symposium on Drug Discovery and Process Research, Belgaum, 10th to 12th February, 2006.

136. Vavia P.R., Francesco Trotta, Shankar Swaminathan, “Formulation of Itraconazole nanosponges” XIII International Cyclodextrin Symposium, Torino, Italy, 14th-17th May, 2006.

137. Patel A.R., Vavia P.R., “Ternary complexation as a Novel approach for Taste masking: studies with Famotidine” XIII International Cyclodextrin Symposium, Torino, Italy, 14th-17th May, 2006. 138. Benival D.M., Vavia P.R., “Inclusion Behavior of Carbamazepine and Oxcarbamazepine: A comparative study” XIII International Cyclodextrin Symposium, Torino, Italy, 14th-17th May, 2006.

139. Shankar Swaminathan and Vavia P.R. “Formulation of Itraconazole glasses: A disordered drug delivery approach” The seventh International symposium of Controlled release society, Indian Chapter, Mumbai, Feb. 2007.

140. Satyen Torne, P.R. Vavia, “Nanosponge Based Drug Delivery System of Paclitaxel” presented at Controlled Release Society, Indian Chapter 2007.

141. Patel A. R., P.R. Vavia, “Triacetin based self emulsifying formulation of a poorly water soluble drug” 59th Indian Pharmaceutical Congress, Dec 2007.

142. Patel A.R., P.R. Vavia, “Effect of β-Cyclodextrin complexation on the intestinal permeability of Fenofibrate” 59th Indian Pharmaceutical Congress, Dec 2007.

143. Shelar D. B., P. R. Vavia, “Development of Carbamazepine extended release formulation as per USP using HPMC hydrophilic matrices” 59th Indian Pharmaceutical Congress, Dec. 2007.

144. Sandip Chavan, Shankar Swaminathan, P. R. Vavia, “Novel multi unit particulate system (MUPS) for effective delivery of Itraconazole” 59th Indian Pharmaceutical Congress, Dec. 2007.

145. Kunal P. Pagar, P. R. Vavia, “Synthesis and characterization of L-lactide- depsipeptide copolymer and its application in nanoparticle synthesis” 59th Indian Pharmaceutical Congress, Dec 2007.

146. Gosavi H. R., P. R. Vavia, “Effects of excipient on the stability of Serratiopeptidase enteric coated tablets” 59th Indian Pharmaceutical Congress, Dec 2007.

147. Wawdhane S.R., P.R. Vavia, “Formulation of extended release matrix tablet of Furosemide using cellulose polymers” 59th Indian Pharmaceutical Congress, Dec 2007.

148. Mali N. D., P. R. Vavia, “Design and evaluation of oral disintegrating tablet of Tramadol Hydrochloride” 59th Indian Pharmaceutical Congress, Dec. 2007.

149. Nagpal Amit, P. R. Vavia, “Development and evaluation of oral extended release tablets of Nalbuphine” 59th Indian Pharmaceutical Congress, Dec. 2007. 150. Mayur Sangwai, P. R. Vavia, “Design and evaluation of yeast encapsulated drug delivery system (YEDDS)” 59th Indian Pharmaceutical Congress, Dec. 2007.

151. Khan M. Majed, P. R. Vavia, “Development of aqueous based enteric coated Aspirin tablets” 59th Indian Pharmaceutical Congress, Dec.2007.

152. Ansari Khalid Akhtar, P. R. Vavia, “Development of directly compressible extended release once daily tablet of Felodipine” 59th Indian Pharmaceutical Congress, Dec. 2007.

153. Kunal Pagar, Shankar Swaminathan, P. R. Vavia, “Investigation of solution state interaction of nanosponges and various poorly soluble drugs by Ultraviolet spectroscopy” 59th Indian Pharmaceutical Congress, Dec. 2007.

154. F. Trotta, R. Cavalli, S. Swaminathan, C. Sarzanini, P. R. Vavia. “Novel functionalized nanosponges: synthesis, characterization, safety assessment, cytotoxicity testing and interaction studies” The XIV International Cyclodextrin Symposium, Kyoto, Japan, May 2008.

155. R. Cavalli, F. Trotta, P. R. Vavia , S. Swaminathan, M. Trotta, “Nanosponge based prolonged release injectable formulations of camptothecin” The XIV International Cyclodextrin Symposium, Kyoto, Japan, May 2008.

156. Gaurav Goyal, Vavia P.R., “Design and evaluation of drug-in-adhesive fentanyl transdermal bioequivalent therapeutic system” 35th Annual Meeting of CRS, New York, USA , July 2008.

157. Gosavi H.R., Vavia P.R., “Evaluation of Kollidon® SR in once a day sustained release tablets of trimetazidine hydrochloride” 60th Indian Pharmaceutical Congress, Dec. 2008.

158. Shankar Swaminathan, Vavia P. R., Cavalli R., Trotta F. “Nanosponge based drug delivery systems of dexamethasone” 60th Indian Pharmaceutical Congress, Dec. 2008.

159. Majed Khan, Vavia P.R., “Development and validation of stability indicating RP- HPLC method for estimation of pentoprazole in pantoprazole enteric coated tablets” 60th Indian Pharmaceutical Congress, Dec. 2008. 160. Wawdhane S.R., Vavia P.R., “A new multiparticulate controlled porosity osmotic pump(CPOP) of oxybutynin hydrochloride” 60th Indian Pharmaceutical Congress, Dec. 2008.

161. Chavan S.S., Vavia P.R., “Effect of calcium hydrogen phosphate dihydrate and calcium hydrogen phosphate anhydrous on hardness of pyridoxine tablets 50mg a case study” 60th Indian Pharmaceutical Congress, Dec. 2008.

162. Shelar D.B., Vavia P.R., “Tablet formulation studies of Oxcarbazepine-poloxamer binary system” 60th Indian Pharmaceutical Congress, Dec. 2008.

163. Mali N.D., Vavia P.R., “Design of bi-layer sustained release tablet formulation of Domperidone Maleate” 60th Indian Pharmaceutical Congress, Dec. 2008.

164. Bramhane D.M., Vavia P.R., “Preparation, evaluation and characterization of lornoxicam: β-cyclodextrin and arginine ternary complex” 60th Indian Pharmaceutical Congress, Dec. 2008.

165. Saindane N.S., Vavia P.R., “Synthesis of water soluble β-cyclodextrin polymers and to explore their application in enhancing solubility of water insoluble drug” 60th Indian Pharmaceutical Congress, Dec. 2008.

166. Sangwai M.B., Vavia P.R., “Effect of various excipients on orally disintegrating tablet of S(-) Amlodipine Besylate” 60th Indian Pharmaceutical Congress, Dec. 2008.

167. Pagar K.P., Ansari K.A., Vavia P.R., “Development and validation of stability indicating HPLC Method for estimation of felodipine in SNEDDS formulation” 60 th Indian Pharmaceutical Congress, Dec. 2008.

168. Darandale S.S., Vavia P.R., “Design and evaluation of novel gastroretentive films of poorly soluble drug” 60th Indian Pharmaceutical Congress, Dec. 2008.

169. Khire A.S., Vavia P.R., “Studies on novel soft high solids containing pressure sensitive adhesive for transdermal therapeutic system” 60th Indian Pharmaceutical Congress, Dec. 2008.

170. Meer T.S., Vavia P.R., “Development of enteric coated multiparticulate drug delivery system for aspirin” 60th Indian Pharmaceutical Congress, Dec. 2008. 171. Pawar S.K., Vavia P.R., “Preparation and evaluation of self-microemulsifying drug delivery system of Tacrolimus” 60th Indian Pharmaceutical Congress, Dec. 2008.

172. Gosavi H. R., Vavia P. R. “ Novel approaches for Solubilization of Nisoldipine” 9th Controlled Released Scociety- Indian chapter, Feb. 2009

173. Swaminathan S., Vavia P. R.,Trotta. F, Cavalli. R “Existence of Crystalline and Para-crystalline forms of Nanosponges of Beta-cyclodextrin and its Effect on Solubilization of a Model Drug”9th Controlled Released Society- Indian chapter, Feb. 2009.

174. Vavia P.R., Swaminathan S, Torne S.J., Trotta F., Cavalli R., “Nanosponges: Fabrication, Characterization and Applications in Drug delivery”, An oral invited presentation at the II Italian Cyclodextrin symposium held in Asti, Italy in May 2009.

175. Shankar Swaminathan, Pradeep Vavia, Manuela Donalisio , Maria Eugenia Carlotti, Francesco Trotta, David Lembo , Roberta Cavalli, “Characterization Of Antiviral Activity Of Acyclovir-Loaded Carboxylated Nanosponges”, a poster Presentation at the II Italian Cyclodextrin symposium held in Asti, Italy in May 2009.

176. Shankar Swaminathan*, Pradeep R. Vavia, Francesco Trotta, Roberta Cavalli, Loredana Serpe, Gian Paolo Zara. “Novel Functionalized Beta Cyclodextrin Nanosponge Based Stable Formulation Of Camptothecin And In Vitro Cytotoxicity Evaluation”, A poster presented at the Fifth Asian cyclodextrin conference in Busan, Korea in May 2009.

177. Shankar Swaminathan, Pradeep R. Vavia, Ansari Khalid Akhter, Francesco Trotta, Roberta Cavalli, “New applications of Cyclodextrin Based Nanosponges”, An Invited presentation at the Fifth Asian Cyclodextrin conference in Busan, Korea in May 2009.

178. Ansari Khalid Akhter, P. R. Vavia, Francesco trotta, Roberta Cavalli, “Novel Beta Cyclodextrin for Delivery of Resveratrol In vitro Characterisation, Cytotoxicity and permeation Study” The 5th Asian Cyclodextrin Conference(ACC2009), May 2009 .

179. Hemgir Gosavi, P. R. Vavia, “Development and validation of simultaneous analysis of atenolol and hydrochlorothiazide by high performance liquid chromatography” 21st International Symposium on Pharmaceutical and Biomedical Analysis 2009. 180. Dinesh M Bramhane, Pradeep R. Vavia, Poster Presentation entitled: Inclusion Complexation of Weakly Acidic NSAID with β -Cyclodextrin: Selection of Arginine, an Amino Acid, As a Novel Ternary Component, First European Cyclodextrin Conference 11th -13th Oct 2009, Aalborg, Denmark. 181. Nilesh S. Siandane, Pradeep R. Vavia, Poster Presentation Entitled : Synthesis and Characterization of Amphiphilic Star Copolymer of Beta-cyclodextrin and Polypropylene Oxide and Their Application as Nanocarrier, First European Cyclodextrin Conference 11th -13th Oct 2009, Aalborg, Denmark. 182. Ansari Khalid Akhter, P. R. Vavia, Francesco trotta, Roberta Cavalli, Poster Presenatation: Nanosponges as long term oxygen delivery Carrrier, Annual Meeting Controlled Release Society (CRS) 2009, Denmark. 183. Sharad Wawdhane, P. R. Vavia, A Multiparticulate Based Controlled Porosity Osmotic Pump (CPOP) of Oxybutynin HCl, AAPS Annual Meeting and Exposition, 2009, LA, USA. 184. Mayur Sangwai, P. R. Vavia, Effect of various formulation variables on encapsulation efficiency and integrity of preformed yeast biocapsules for oral itraconazole delivery, AAPS Annual Meeting and Exposition, 2009, LA, USA. 185. Mali N.D., Vavia P.R., “Development and validation of stability indicating isocratic RP-HPLC method for analysis of domperidone in domperidone sustained release tablets” 61st Indian Pharmaceutical Congress, Dec. 2009.

186. Shelar D.B., Vavia P.R., “Preparation and characterization glass solutions of poorely soluble drug using hot melt extrusion technique” 61st Indian Pharmaceutical Congress, Dec. 2009.

187. Bramhane D.M., Vavia P.R., “New LC method for determination of lornoxicam assay and impurities content in tablet formulation” 61st Indian Pharmaceutical Congress, Dec. 2009.

188. Pagar K.P., Vavia P.R., “Development of timed release film-coated felodipine tablets for chronotherapeutic application in heart” 61st Indian Pharmaceutical Congress, Dec. 2009. 189. Darandale S.S., Vavia P.R., “Gastroretentive drug loaded polymeric films-method of preparation and characterization” 61st Indian Pharmaceutical Congress, Dec. 2009.

190. Vora L. K., Vavia P.R., “Enhancement of solubility and dissolution rate of lercanidipine with parent cyclodextrin and modified cyclodextrin” 61st Indian Pharmaceutical Congress, Dec. 2009.

191. Wavikar P., Vavia P.R., “Topical solid lipid nanoparticles of antimycotic agent:terbinafine HCL” 61st Indian Pharmaceutical Congress, Dec. 2009.

192. Jadhav N., Vavia P.R., “Enteric coated multiple unit particulate system of pantoprazole sodium sesquehydrate” 61st Indian Pharmaceutical Congress, Dec. 2009.

193. Swaminathan S., Sharad W., Vavia P.R., “Development and validation of a stability indicating isocratic RP-HPLC method for estimation of itraconazole from a novel tablet formulation” 61st Indian Pharmaceutical Congress, Dec. 2009.

194. Sharad W., Vavia P. R. “ A novel extended release bilayer matrix tablet of furosemide, 10th Controlled Released Scociety- Indian chapter, Feb. 2010

195. Shelar D.B., Vavia P. R. “ SMECTITE clay as a controlled release material for Carbamazepine delivery” 10th Controlled Released Scociety- Indian chapter, Feb. 2010

196. Shelar D.B., Vavia P. R. “Self-Nanoemulsifying Drug Delivery Systems of Isradipine: Design and Optimization” 37th annual meeting and exposition of controlled release society, Oregon, USA, 2010

197. Mali N.D., Vavia P.R. “Development and validation of RP-HPLC method for determination of methylparaben sodium, propyl paraben sodium and potassium sorbate in citicoline oral solution” 62nd Indian Pharmaceutical Congress, Dec. 2010.

198. Gavhane S.P., Vavia P.R., “Development and evaluation of monolithic transdermal patch for chronic pain” 62nd Indian Pharmaceutical Congress, Dec. 2010.

199. Saindane N.S., Pagar K.P., Vavia P.R. “Controlled release formulation of glipizide based on interpolymer complexation of carbopol-hydroxypropyl methyl cellulose, 62nd Indian Pharmaceutical Congress, Dec. 2010. 200. Kumbhar D.P., Vavia P.R. “Topical lornxicam niosomal gel formulation for treatment of rheumatoid arthritis” 62nd Indian Pharmaceutical Congress, Dec. 2010.

201. Jasmin D.M., Vavia P.R. “Preparation of ezetimibe nanocrystals by nanoprecipitation method for enhanced aqueous solubility and dissolution rate” 62nd Indian Pharmaceutical Congress, Dec. 2010.

202. Brahmne D.M., Vavia P.R. “ Crosslinked β-cyclodextrin polymer: Novel excipients for controlled drug delivery system” 62nd Indian Pharmaceutical Congress, Dec. 2010.

203. Vora L.K., Vavia P.R. “Ternary complexation of repaglinide with Hydroxypropyl β-cyclodextrin and meglumine for solubility and dissolution enhancement” 62nd Indian Pharmaceutical Congress, Dec. 2010.

Complete list of publications (peer reviewed + others)

International:

1. Patel K, Tyagi M, Monpara J, Vora L, Gupta S, Vavia P. Arginoplexes: an arginine- anchored nanoliposomal carrier for gene delivery. Journal of Nanoparticle Research. 2014;16(4).

2. Pagar KP, Sardar SM, Vavia PR. Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of alzheimer's disease. Journal of Biomedical Nanotechnology. 2014;10(3):415-26.

3. Khire A, Vavia P. Electron capture detection of oxybutynin in plasma: Precolumn derivatization approach and application to a pharmacokinetic study. Analytical Methods. 2014;6(5):1455-61.

4. Wavikar P, Vavia P. Nanolipidgel for enhanced skin deposition and improved antifungal activity. AAPS PharmSciTech. 2013;14(1):222-33. 5. Torne S, Darandale S, Vavia P, Trotta F, Cavalli R. Cyclodextrin-based nanosponges: effective nanocarrier for tamoxifen delivery. Pharmaceutical development and technology. 2013;18(3):619-25.

6. Swaminathan S, Vavia PR, Trotta F, Cavalli R, Tumbiolo S, Bertinetti L, et al. Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2013;76(1-2):201-11.

7. Swaminathan S, Vavia PR, Trotta F, Cavalli R. Nanosponges encapsulating dexamethasone for ocular delivery: Formulation design, physicochemical characterization, safety and corneal permeability assessment. Journal of Biomedical Nanotechnology. 2013;9(6):998-1007.

8. Swaminathan S, Sangwai M, Wawdhane S, Vavia P. Soluble itraconazole in tablet form using disordered drug delivery approach: Critical scale-up considerations and bio-equivalence studies. AAPS PharmSciTech. 2013;14(1):360-74.

9. Shelar DB, Pawar SK, Vavia PR. Fabrication of isradipine nanosuspension by anti- solvent microprecipitation-high-pressure homogenization method for enhancing dissolution rate and oral bioavailability. Drug Delivery and Translational Research. 2013;3(5):384-91.

10. Sardar S, Pagar K, Sangwai M, Vavia P. Monolithic osmotic system of lornoxicam using amorphous ternary cyclodextrin complex as a core. International Journal of PharmTech Research. 2013;5(2):730-45.

11. Sangwai M, Vavia P. Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: Improved solubility and reduced pharmacokinetic variability. International Journal of Pharmaceutics. 2013;453(2):423-32.

12. Saindane NS, Pagar KP, Vavia PR. Nanosuspension based in situ gelling nasal spray of carvedilol: Development, in vitro and in vivo characterization. AAPS PharmSciTech. 2013;14(1):189-99.

13. Patel K, Sarma V, Vavia P. Design and evaluation of Lumefantrine - Oleic acid self nanoemulsifying ionic complex for enhanced dissolution. DARU, Journal of Pharmaceutical Sciences. 2013;21(1). 14. Patel K, Pati A, Mehta M, Gota V, Vavia P. Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): A safe and efficacious alternative to taxol®. Journal of Biomedical Nanotechnology. 2013;9(12):1996-2006.

15. Pagar KP, Vavia PR. Poly[LA-(Glc-Leu)] copolymer as a carrier for ocular delivery of ciprofloxacin: Formulation, characterization and in vivo biocompatibility study. Therapeutic Delivery. 2013;4(5):553-65.

16. Pagar K, Vavia P. Rivastigmine-loaded L-lactide-depsipeptide polymeric nanoparticles: Decisive formulation variable optimization. Scientia Pharmaceutica. 2013;81(3):865-85.

17. Nandedkar TD, Sagvekar P, Thakur B, Navlakhe R, Chitnis S, Mahale SD, et al. Polymeric nanoparticle formulation of octapeptide (NP-OP): In vitro release and in vivo effect in common marmosets, Callithrix jacchus Linn. Indian Journal of Experimental Biology. 2013;51(12):1055-62.

18. Mali N, Darandale S, Vavia P. Niosomes as a vesicular carrier for topical administration of minoxidil: Formulation and in vitro assessment. Drug Delivery and Translational Research. 2013;3(6):587-92.

19. Lembo D, Swaminathan S, Donalisio M, Civra A, Pastero L, Aquilano D, et al. Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. International Journal of Pharmaceutics. 2013;443(1-2):262-72.

20. Kumbhar D, Wavikar P, Vavia P. Niosomal gel of lornoxicam for topical delivery: In vitro assessment and pharmacodynamic activity. AAPS PharmSciTech. 2013;14(3):1072-82.

21. Khire A, Vavia P. Effect of permeation enhancers on dynamic mechanical properties of acrylate pressure sensitive adhesives. International Journal of Pharmaceutics. 2013;458(1):141-7.

22. Darandale SS, Vavia PR. Cyclodextrin-based nanosponges of curcumin: Formulation and physicochemical characterization. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2013;75(3-4):315-22. 23. Chavan SS, Ingle SG, Vavia PR. Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide. Drug Delivery and Translational Research. 2013;3(5):402-8.

24. Bramhane DM, Jadhav NV, Vavia PR. Development, characterisation and evaluation of supersaturated triglyceride free drug delivery (s-TFDDS) of lornoxicam. Drug Delivery and Translational Research. 2013;3(5):392-401.

25. Bandarkar FS, Vavia PR. Physico-chemical characterization and in vivo pharmacodynamic evaluation of lyophilized meloxicam: β-cyclodextrin inclusion complexes. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;5(3):159-65.

26. Swaminathan S, Darandale S, Vavia PR. Technology improves bioavailability of some drugs, offers formulation versatility and holds potential for a revolution in nano therapies. Pharmaceutical Formulation and Quality. 2012(6).

27. Saindane N, Vavia P. Osmotic pellet system comprising osmotic core and in- process amorphized drug in polymer-surfactant layer for controlled delivery of poorly water-soluble drug. Journal of Pharmaceutical Sciences. 2012;101(9):3169- 79.

28. Pawar SK, Vavia PR. Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech. 2012;13(1):254-61.

29. Pawar SK, Badhwar AJ, Kharas F, Khandare JJ, Vavia PR. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. International Journal of Pharmaceutics. 2012;436(1- 2):183-93.

30. Pagar KP, Vavia PR. Felodipine b-cyclodextrin complex as an active core for time delayed chronotherapeutic treatment of hypertension. Acta Pharmaceutica. 2012;62(3):395-410.

31. Goyal G, Vavia PR. Complexation approach for fixed dose tablet formulation of lopinavir and ritonavir: An anomalous relationship between stability constant, dissolution rate and saturation solubility. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2012;73(1-4):75-85. 32. Trotta F, Cavalli R, Martina K, Biasizzo M, Vitillo J, Bordiga S, et al. Cyclodextrin nanosponges as effective gas carriers. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2011;71(1-2):189-94.

33. Sangwai MB, Vavia PR. Effect of decisive formulation variables on bioencapsulation efficiency and integrity of yeast biocapsules for oral itraconazole delivery. Journal of Microencapsulation. 2011;28(4):311-22.

34. Saindane NS, Bramhane DM, Vavia PR. Synthesis and characterization of amphiphilic star copolymer of beta-cyclodextrin and polypropylene oxide and their application as nanocarriers. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2011;69(3-4):383-92.

35. Bramhane DM, Saindane NS, Vavia PR. Inclusion complexation of weakly acidic NSAID with β-cyclodextrin: Selection of arginine, an amino acid, as a novel ternary component. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2011;69(3-4):453-60.

36. Bandarkar FS, Vavia PR. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin. Drug Development and Industrial Pharmacy. 2011;37(11):1318-28.

37. Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech. 2011;12(1):279-86.

38. Ansari KA, Torne SJ, Vavia PR, Trotta F, Cavalli R. Paclitaxel loaded nanosponges: In-vitro characterization and cytotoxicity study on MCF-7 cell line culture. Current Drug Delivery. 2011;8(2):194-202.

39. Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Delivery. 2010;17(6):419-25.

40. Swaminathan S, Pastero L, Serpe L, Trotta F, Vavia P, Aquilano D, et al. Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. European Journal of Pharmaceutics and Biopharmaceutics. 2010;74(2):193-201. 41. Swaminathan S, Cavalli R, Trotta F, Ferruti P, Ranucci E, Gerges I, et al. In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of β-cyclodextrin. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2010;68(1):183-91.

42. Patel AR, Vavia PR. SMEDDS incorporated polymer matrix: A floating dosage form solution for drugs with poor gastric solubility. Pharmaceutical Technology Europe. 2010;22(3):36-42.

43. Patel AR, Vavia PR. Evaluation of synthesized cross linked polyvinyl alcohol as potential disintegrant. Journal of Pharmacy and Pharmaceutical Sciences. 2010;13(2):114-27.

44. Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F, Vavia P. Nanosponge formulations as oxygen delivery systems. International Journal of Pharmaceutics. 2010;402(1-2):254-7.

45. Puthli SP, Vavia PR. Fabrication, characterization and in vivo studies of biodegradable gamma sterilized injectable microparticles for contraceptionVavia. Pharmaceutical Development and Technology. 2009;14(3):278-89.

46. Puthli S, Vavia PR. Stability studies of microparticulate system with piroxicam as model drug. AAPS PharmSciTech. 2009;10(3):872-80.

47. Puthli S, Vavia P. Formulation and performance characterization of radio-sterilized "Progestin-only" microparticles intended for contraception. AAPS PharmSciTech. 2009;10(2):443-52.

48. Bandarkar FS, Vavia PR. A stability indicating HPLC method for the determination of meloxicam in bulk and commercial formulations. Tropical Journal of Pharmaceutical Research. 2009;8(3):257-64.

49. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine: Nanotechnology, Biology, and Medicine. 2009;5(1):90-5.

50. Agnihotri SM, Vavia PR. Drug loaded poly[Lac(Glc-Leu)] microparticles: Formulation and release characteristics. Colloids and Surfaces B: Biointerfaces. 2009;74(1):336-9. 51. Agnihotri SM, Vavia PR. Pharmacokinetics of intramuscular microparticle depot of valdecoxib in an experimental model Pharmacokinetics of intramuscular microparticle depot. Drug Development and Industrial Pharmacy. 2009;35(9):1043-7.

52. Puthli S, Vavia P. Gamma irradiated micro system for long-term parenteral contraception: An alternative to synthetic polymers. European Journal of Pharmaceutical Sciences. 2008;35(4):307-17.

53. Patel AR, Vavia PR. Preparation and evaluation of taste masked famotidine formulation using drug/β-cyclodextrin/polymer ternary complexation approach. AAPS PharmSciTech. 2008;9(2):544-50.

54. Jadhav GS, Vavia PR. Physicochemical, in silico and in vivo evaluation of a danazol- β-cyclodextrin complex. International Journal of Pharmaceutics. 2008;352(1-2):5- 16.

55. Adhikary A, Vavia PR. Bioadhesive ranitidine hydrochloride for gastroretention with controlled microenvironmental pH. Drug Development and Industrial Pharmacy. 2008;34(8):860-9.

56. Torne SJ, Torne JS, Vavia PR, Singh SK, Kishore N. Cyclodextrin based drug delivery system of protease inhibitor - Nelfinavir mesylate. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2007;57(1-4):689-97.

57. Swaminathan S, Vavia PR, Trotta F, Torne S. Formulation of betacyclodextrin based nanosponges of itraconazole. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2007;57(1-4):89-94.

58. Patel AR, Vavia PR. Nanotechnology and pharmaceutical inhalation aerosols. Indian Journal of Experimental Biology. 2007;45(2):166-74.

59. Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self- microemulsifying drug delivery system) containing fenofibrate. AAPS Journal. 2007;9(3):E344-E52.

60. Jadhav GS, Vavia PR, Nandedkar TD. Danazol-β-cyclodextrin binary system: A potential application in emergency contraception by the oral route. AAPS PharmSciTech. 2007;8(2). 61. Torne JS, Vavia PR. Inclusion complexation of Anti-HIV drug with β-cyclodextrin. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2006;56(1-2):253-9.

62. Tayade P, Vavia P. Inclusion complexes of Ketoprofen with β-cyclodextrins: Oral pharmacokinetics of ketoprofen in human. Indian Journal of Pharmaceutical Sciences. 2006;68(2):164-70.

63. Patel AR, Vavia PR. Effect of hydrophilic polymer on solubilization of fenofibrate by cyclodextrin complexation. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2006;56(1-2):247-51.

64. Jadhav GS, Patel AR, Vavia PR, Malde AK, Coutinho EC. Interaction of valdecoxib with β-cyclodextrin: Experimental and molecular modeling studies. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2006;56(1-2):261-73.

65. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. International Journal of Pharmaceutics. 2006;316(1-2):86-92.

66. Chaudhari S, Karnik A, Adhikary A, Tandale R, Vavia P. Simultaneous UV spectrophotometric method for the estimation of cefuroxime axetil and probenecid from solid dosage forms. Indian Journal of Pharmaceutical Sciences. 2006;68(1):59-63.

67. Tayade PT, Vavia PR. Sustained release agglomerates of ibuprofen using natural polymer and thermal gelation technique. Indian Journal of Pharmaceutical Sciences. 2005;67(6):697-702.

68. Chavanpatil MD, Vavia PR. Nasal drug delivery of sumatriptan succinate. Pharmazie. 2005;60(5):347-9.

69. Chavanpatil M, Jain P, Chaudhari S, Shear R, Vavia P. Development of sustained release gastroretentive drug delivery system for ofloxacin: In vitro and in vivo evaluation. International Journal of Pharmaceutics. 2005;304(1-2):178-84.

70. Kotiyan PN, Vavia PR, Bhardwaj YK, Sabarwal S, Majali AB. Electron beam irradiation: A novel technology for the development of transdermal system of isosorbide dinitrate. International Journal of Pharmaceutics. 2004;270(1-2):47-54. 71. Chavanpatil MD, Vavia PR. The influence of absorption enhancers on nasal absorption of acyclovir. European Journal of Pharmaceutics and Biopharmaceutics. 2004;57(3):483-7.

72. Tipre DN, Vavia PR. Acrylate-based transdermal therapeutic system of nitrendipine. Drug Development and Industrial Pharmacy. 2003;29(1):71-8.

73. Tipre DN, Vavia PR. Acrylate-based pressure sensitive adhesive in fabrication of transdermal therapeutic system. Polymers for Advanced Technologies. 2003;14(7):502-7.

74. Makhija SN, Vavia PR. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine: I. Cellulose acetate as a semipermeable membrane. Journal of Controlled Release. 2003;89(1):5-18.

75. Barkume MS, Tayade PT, Vavia PR, Indap MA. Antiproliferative effect of aspirin and its inclusion complex on human MCF-7 and K-562 cancer cells in vitro. Indian Journal of Pharmaceutical Sciences. 2003;65(5):486-91.

76. Agnihotri SM, Vavia PR. Influences of process parameters on nanoparticle preparation performed by a double emulsion ultrasonication technique. Journal of Surface Science and Technology. 2003;19(3-4):183-7.

77. Tipre DN, Vavia PR. Formulation optimization and stability study of transdermal therapeutic system of nicorandil. Pharmaceutical Development and Technology. 2002;7(3):325-32.

78. Makhija SN, Vavia PR. Stability indicating LC method for the estimation of venlafaxine in pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis. 2002;28(6):1055-9.

79. Makhija SN, Vavia PR. Once daily sustained release tablets of venlafaxine, a novel antidepressant. European Journal of Pharmaceutics and Biopharmaceutics. 2002;54(1):9-15.

80. Kotiyan PN, Vavia PR, Bharadwaj YK, Sabarwal S, Majali AB. Electron beam processed transdermal delivery system for administration of an anti-anginal agent. Radiation Physics and Chemistry. 2002;65(6):641-6. 81. Kotiyan PN, Vavia PR. Synthesis and characterization of an acrylate pressure sensitive adhesive for transdermal drug delivery. Polymers for Advanced Technologies. 2002;13(2):137-43.

82. Indap MA, Bhosle SC, Tayade PT, Vavia PR. Evaluation of toxicity and antitumour effects of a hydroxypropyl β-cyclodextrin inclusion complex of quercetin. Indian Journal of Pharmaceutical Sciences. 2002;64(4):349-53.

83. Chavanpatil M, Vavia PR. Enhancement of nasal absorption of acyclovir via cyclodextrins. Journal of Inclusion Phenomena. 2002;44(1-4):137-40.

84. Chavanpatil M, Dawre FD, Shakleya DS, Vavia PR. Enhancement of oral bioavailability of rofecoxib using β-cyclodextrin. Journal of Inclusion Phenomena. 2002;44(1-4):145-9.

85. Tipre DN, Vavia PR. Oxidative degradation study of nitrendipine using stability indicating, HPLC, HPTLC and spectrophotometric method. Journal of Pharmaceutical and Biomedical Analysis. 2001;24(4):705-14.

86. Mare VS, Bharti PV, Vavia PR. Synthesis and characterization of a novel soluble reactive ladder-like polysilsesquioxane with side-chain 2-(4-Chloromethyl phenyl) ethyl groups. Polymers for Advanced Technologies. 2001;12(8):475-81.

87. Makhija SN, Vavia PR. Stability indicating HPTLC method for the simultaneous determination of pseudoephedrine and cetirizine in pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis. 2001;25(3-4):663-7.

88. Kotiyan PN, Vavia PR. Eudragits: Role as crystallization inhibitors in drug-in- adhesive transdermal systems of estradiol. European Journal of Pharmaceutics and Biopharmaceutics. 2001;52(2):173-80.

89. Vavia PR, Adhage NA. Freeze-dried inclusion complexes of tolfenamic acid with β- cyclodextrins. Pharmaceutical Development and Technology. 2000;5(4):571-4.

90. Tipre DN, Vavia PR. Degradation kinetic study of nicorandil using HPTLC method. Indian Drugs. 2000;37(9):412-6.

91. Puthli SP, Vavia PR. Stability indicating HPTLC determination of piroxicam. Journal of Pharmaceutical and Biomedical Analysis. 2000;22(4):673-7. 92. Kotiyan PN, Vavia PR. Stability indicating HPTLC method for the estimation of estradiol. Journal of Pharmaceutical and Biomedical Analysis. 2000;22(4):667-71.

93. Kinalekar MS, Kulkarni SR, Vavia PR. Simultaneous determination of α, β and γ cyclodextrins by LC. Journal of Pharmaceutical and Biomedical Analysis. 2000;22(4):661-6.

94. Dubhashi SS, Vavia PR. HPTLC method to study skin permeation of acylovir. Journal of Pharmaceutical and Biomedical Analysis. 2000;23(6):1017-22.

95. Dubhashi SS, Vavia PR. Stability indicating reverse phase HPLC method for acyclovir. Indian Drugs. 2000;37(10):464-8.

96. Adhage NA, Vavia PR. β-cyclodextrin inclusion complexation by milling. Pharmacy and Pharmacology Communications. 2000;6(1):13-7.

97. Vavia PR, Tayade PT. Inclusion Complexation of Ketoprofen with β-Cyclodextrins. Indian Journal of Pharmaceutical Sciences. 1999;61(1-6):97-9.

98. Vavia PR, Adhage NA. Inclusion complexation of nimesulide with β-cyclodextrins. Drug Development and Industrial Pharmacy. 1999;25(4):543-5.

99. Tipre DN, Vavia PR. Estimation of Sumatriptan succinate in pharmaceutical dosage form by spectrophotometric and HPTLC method. Indian Drugs. 1999;36(8):501-5.

100. Puthli SP, Vavia PR. Poly(lactide-co-glycolide) microparticulate system of piroxicam. Proceedings of the Controlled Release Society. 1999(26):1110-1.

101. Kotiyan PN, Vavia PR. Eudragit®RL PO based drug-in-adhesive transdermal system of estradiol. Proceedings of the Controlled Release Society. 1999(26):397- 8.

102. Vavia PR, Puthli SP. Poly (lactide-co-glycolide) microspheres of levonorgestrel for parenteral contraception. Journal of Pharmacy and Pharmacology. 1998;50(SUPPL. 9):144.

103. Indap MA, Bhosle SC, Vavia PR, Tayade PT. Quercetin-cyclodextrin complex and it's chemotherapeutic investigations in cancer. Indian Drugs. 1998;35(9):545-9.

104. Bhalla HL, Vavia PR, Samuel G, Sivaprasad N. Development of radioimmunoassay. I. Preparation of radiolabeled tracers theophylline. Journal of Radioanalytical and Nuclear Chemistry. 1997;220(1):73-6. 105. Sapre AG, Ramjilal, Sivaprasad N, Vavia PR. Synthesis of an immunogen and a novel radiotracer of estradiol. Journal of Radioanalytical and Nuclear Chemistry. 1996;214(4):291-301.

106. Tike CA, Hegde DA, Naik MM, Vavia PR, Tipnis HP. Bioequivalence studies of angiotensin converting enzyme inhibitors. Part VII (captopril). Indian Drugs. 1995;32(4):155-9.

107. Tike CA, Hegde DA, Naik MM, Vavia PR, Tipnis HP. Bioequivalence studies of angiotensin converting enzyme inhibitors: Part VIII - Pharmacokinetic interaction between captopril and hydrochlorthiazide. Indian Drugs. 1995;32(5):217-24.

108. Naik MM, Hegde DA, Tike CA, Vavia PR, Tipnis HP. Pharmacokinetic studies of new angiotensin converting enzyme inhibitors marketed abroad - Part VI (Quinapril, Benazepril and Trandolapril). Indian Drugs. 1995;32(3):116-9.

109. Hegde DA, Naik MM, Tike CA, Vavia PR, Tipnis HP. Bioequivalence studies of angiotensin converting enzyme inhibitors: Part V - Pharmacokinetic interaction between lisinopril and hydrochlorothiazide. Indian Drugs. 1995;32(2):84-9.

110. Tike CA, Vavia PR, Naik MM, Tipnis HP. Bioequivalence studies of angiotensin converting enzyme inhibitors: Part II (enalapril maleate). Indian Drugs. 1994;31(4):155-9.

111. Naik MM, Tike CA, Vavia PR, Tipnis HP. Pharmacokinetics studies of new angiotensin converting enzyme inhibitors marketed in India and abroad: Part III (perindopril and cilazapril). Indian Drugs. 1994;31(5):197-200.

112. Hegde DA, Naik MM, Vavia PR, Tipnis HP. Bioequivalence studies of angiotensin converting enzyme inhibitors: Part IV - Pharmacokinetic interaction between enalapril maleate and hydrochlorthiazide. Indian Drugs. 1994;31(10):479-84.

113. Tike CA, Vavia PR, Tipnis HP. Bioequivalence studies of angiotensin converting enzyme inhibitors: Part - I (lisinopril). Indian Drugs. 1992;29(13):601-4.

National: (21) 1. Bhalla H.L. and Vavia P.R., Effect of enhancers on in-vitro permeation of ketoprofen, Indian Drugs, 26(5): 247, 1989. 2. Tike C.A., Vavia P.R., and Tipnis H.P., Bioequivalence studies of angiotensin converting enzyme inhibitors : Part I (Lisinopril), Indian Drugs, 29(13) : 601, 1992.

3. Vavia P.R., Tike C.A., Naik M. and Tipnis H.P., Bioequivalence studies of angiotensin converting enzyme inhibitors : Part II (Enalapril Maleate), Indian Drugs, 31(4) : 155,1994.

4. Vavia P.R., Tike C.A., Naik M. and Tipnis H.P., Pharmacokinetic studies of new angiotensin converting enzyme inhibitors marketed in India and abroad: Part III (Perindopril and Cilazapril), Indian Drugs, 31(5) : 197, 1994.

5. Vavia P.R., Tike C.A., Naik M. and Tipnis H.P., Hegde D.A. Bioequivalence studies of angiotensin converting enzyme inhibitors: Part IV Pharmacokinetic interaction between enalapril maleate and hydrochlorthiazide, Indian Drugs, 31(10) : 479, 1994.

6. Vavia P.R., Tike C.A., Naik M. and Tipnis H.P., Hegde D.A. Bioequivalence studies of angiotensin converting enzyme inhibitors: Part V Pharmacokinetic interaction between lisinopril and hydrochlorthiazide, Indian Drugs, 32(2) : 84, 1995.

7. Vavia P.R., Tike C.A., Naik M. and Tipnis H.P., Hegde D.A. Pharmacokinetic studies of new angiotensin converting enzyme inhibitors: Part VI (Quinapril, Benazaril and Tendaropril), Indian Drugs, 32(3) : 116, 1995.

8. Vavia P.R., Tike C.A., Naik M. and Tipnis H.P., Hegde D.A.,Bioequivalence studies of angiotensin converting enzyme inhibitors: Part VII (Captopril), Indian Drugs, 34(4) : 155, 1995.

9. Vavia P.R., Tike C.A., Naik M. and Tipnis H.P., Hegde D.A., Bioequivalence studies of angiotensin converting enzyme inhibitors: Part VIII Pharmacokinetic interaction between captopril and hydrochlorthiazide, Indian Drugs, 32(5) : 217, 1995.

10. Indap M.A., Bhosle S.C., Vavia P.R. and Tayade P.T., Quercetin-cyclodextrin complex and it's chemotherapeutic investigations in cancer, Indian Drugs, 35(9) Sep. 1998. 11. Vavia P.R. and Tayade P.T., Inclusion complexation of ketoprofen with - cyclodextrins, Indian Journal of Pharmaceutical Sciences, 61(2): 97-99, 1999.

12. Tipre D.N. and Vavia P.R., Estimation of sumatriptan succinate in pharmaceutical dosage from by spectrophotometric and HPTLC method, Indian Drugs, 36(8) August, 1999.

13. Tipre D.N. and Vavia P.R, Degradation Kinetic study of nicorandil using HPTLC method, Indian Drugs, 37(9) 412-416, 2000.

14. Dubhashi S.S. and Vavia P.R., Stability indicating reverse phase HPLC method for Acyclovir, Indian Drugs, 37 (10) 464-468, 2000.

15. Indap, M.A., Bhosle, S.C., Tayade, P.T., Vavia, P.R., Evaluation of toxicity and antitumour effects of a hydroxypropyl β-cyclodextrin inclusion complex of quercetin, Indian Journal of Pharmaceutical Sciences 64 (4), 349-353, 2002

16. Tandale R.S., Vavia P.R., Meghana Abhyankar, Dilip pawar, Comparative evaluation of Anti-inflammatory efficacy of Roff-Gel with other marketed topical gels, Indian Medical Gazette, 302-309, August 2003.

17. Barkume M.S., Tayade P.T., Vavia P.R., Indap M.A., Antiproliferative effect of Aspirin and its inclusion complex on human MCF-7 and K-562 cancer cells in- vitro, Indian Journal of Pharmaceutical sciences, 65(5), 486-491, 2003.

18. Jadhav, G.S., Vavia, P.R., Development and pharmacodynamic evaluation of tablet containing inclusion complex of valdecoxib with β-cyclodextrin, Indian J. Pharm. Sci. 60, 525-526, 2004.

19. Tayade, P.T., Vavia, P.R., Sustained release agglomerates of ibuprofen using natural polymer and thermal gelation technique, Indian Journal of Pharmaceutical Sciences 67 (6), pp. 697-702, 2005.

20. Chaudhari S.V., Karnik Ashwani, Adhikary Anuradha, Tandale R.S.,Vavia P.R., “Simultaneous UV spectrophotometric method for the estimation of cefuroxime axetil and probenecid from solid dosage forms ”Indian Journal of Pharmaceutical Sciences, , 68(1), 1-132, 2006.

21. A.R. Patel and P.R. Vavia, Nanotechnology and pharmaceutical inhalation aerosols, Indian Journal of Experimental Biology, 45, 166-174, 2007.